Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Issue 1 (January 2014)

• Record Type: Journal Article
• Authors: Havari, Evis; Turner, Michael J.; Campos‐Rivera, Juanita; Shankara, Srinivas; Nguyen, Tri‐Hung; Roberts, Bruce; Siders, William; Kaplan, Johanne M.
• Is Part Of: Immunology. Volume 141:Issue 1(2014:Jan.)
• Page Start: 123
• Page End: 131
• Publication Date: 2014-01
• Subjects: Immunology -- Periodicals
• DOI: 10.1111/imm.12178
• Languages: English
• ISSNs: 0019-2805

Abstract

<abstract abstract-type="main" id="imm12178-abs-0001"> <title>Summary</title> <p>Alemtuzumab is a humanized monoclonal antibody specific for the CD52 protein present at high levels on the surface of B and T lymphocytes. In clinical trials, alemtuzumab has shown a clinical benefit superior to that of interferon‐β in relapsing–remitting multiple sclerosis patients. Treatment with alemtuzumab leads to the depletion of circulating lymphocytes followed by a repopulation process characterized by alterations in the number, proportions and properties of lymphocyte subsets. Of particular interest, an increase in the percentage of T cells with a regulatory phenotype (Treg cells) has been observed in multiple sclerosis patients after alemtuzumab. Since Treg cells play an important role in the control of autoimmune responses, the effect of alemtuzumab on Treg cells was further studied <italic>in vitro</italic>. Alemtuzumab effectively mediated complement‐dependent cytolysis of human T lymphocytes and the remaining population was enriched in T cells with a regulatory phenotype. The alemtuzumab‐exposed T cells displayed functional regulatory characteristics including anergy to stimulation with allogeneic dendritic cells and ability to suppress the allogeneic response of autologous T cells. Consistent with the observed increase in Treg cell frequency, the CD25<sup>hi</sup> T‐cell population was necessary for the suppressive activity of alemtuzumab‐exposed T cells. The mechanism of this suppression was found to be dependent on both cell–cell contact and interleukin‐2 consumption. These findings suggest that an alemtuzumab‐mediated increase in the proportion of Treg cells may play a role in promoting the long‐term efficacy of alemtuzumab in patients with multiple sclerosis.</p> </abstract>